Your browser doesn't support javascript.
loading
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean, Elias; Demolis, Pierre; Moreau, Alexandre; Hemmings, Robert James; O'Connor, Daniel; Brown, David; Shepard, Terry; Abadie, Eric; Pignatti, Francesco.
Affiliation
  • Pean E; European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK. Elias.Pean@ema.europa.eu
Oncologist ; 17(4): 543-9, 2012.
Article in En | MEDLINE | ID: mdl-22477727
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Taxoids Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Taxoids Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Country of publication: